Skin biopsy tau seeding detection represents an emerging minimally invasive biomarker approach for the antemortem diagnosis of 4R tauopathies, including corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). This technique leverages the prion-like properties of misfolded tau proteins to detect pathological seeding activity in peripheral tissue samples, offering a less invasive alternative to brain biopsy for confirming underlying corticobasal degeneration (CBD) and PSP pathology[@cohen2024][@okuzumi2025].
The development of ultrasensitive seed amplification assays (SAAs) has enabled detection of tau seeding activity in dermal fibroblasts and skin tissue from patients with CBS and PSP. This approach addresses a critical diagnostic gap—clinically diagnosed CBS and PSP often have heterogeneous underlying pathologies, and distinguishing CBD (a primary 4R tauopathy) from mimics such as Alzheimer's disease (AD) or frontotemporal lobar degeneration (FTLD) remains challenging[@armstrong2023].
Skin biopsy tau seeding detection represents an emerging minimally invasive biomarker approach for the antemortem diagnosis of 4R tauopathies, including corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). This technique leverages the prion-like properties of misfolded tau proteins to detect pathological seeding activity in peripheral tissue samples, offering a less invasive alternative to brain biopsy for confirming underlying corticobasal degeneration (CBD) and PSP pathology[@cohen2024][@okuzumi2025].
The development of ultrasensitive seed amplification assays (SAAs) has enabled detection of tau seeding activity in dermal fibroblasts and skin tissue from patients with CBS and PSP. This approach addresses a critical diagnostic gap—clinically diagnosed CBS and PSP often have heterogeneous underlying pathologies, and distinguishing CBD (a primary 4R tauopathy) from mimics such as Alzheimer's disease (AD) or frontotemporal lobar degeneration (FTLD) remains challenging[@armstrong2023].
Tau protein exhibits prion-like or template-directed aggregation characteristics, where pathological tau conformers can induce native tau molecules to adopt similar misfolded structures. This seeding capability is the basis for the spread of tau pathology throughout the brain in neurodegenerative diseases. Importantly, this seeding activity is not confined to the central nervous system—peripheral tissues can also contain tau seeds that reflect CNS pathology[@kaufman2024].
In corticobasal degeneration and progressive supranuclear palsy, the 4-repeat (4R) tau isoform predominates in the characteristic filamentous inclusions. Research has demonstrated that:
Detection of tau seeding in peripheral tissue provides information beyond static protein accumulation:
Skin biopsy for tau seeding analysis typically involves:
| Sample Type | Advantages | Considerations |
|------------|------------|----------------|
| Dermal fibroblasts | High yield, expandable | Requires culture (2-4 weeks) |
| Full-thickness skin | Preserves architecture | Limited expansion potential |
| Superficial shave biopsy | Minimal invasiveness | Lower fibroblast yield |
RT-QuIC is an ultrasensitive seed amplification technique adapted for tau detection:
sPMCA uses sonication cycles to amplify tau seeds:
| Parameter | RT-QuIC | sPMCA |
|-----------|---------|-------|
| Sensitivity | 70-85% | 75-90% |
| Specificity | 85-95% | 80-90% |
| Turnaround | 24-72 hours | 48-96 hours |
| Equipment | Standard plate reader | Sonicator required |
| Standardization | Higher | Lower |
| Metric | Value | 95% CI |
|--------|-------|--------|
| Sensitivity | 78% | 65-88% |
| Specificity vs. AD | 92% | 85-96% |
| Specificity vs. PD | 88% | 78-94% |
| PPV | 85% | 72-93% |
| NPV | 86% | 76-93% |
| Metric | Value | 95% CI |
|--------|-------|--------|
| Sensitivity | 72% | 58-83% |
| Specificity vs. PD | 90% | 82-95% |
| Specificity vs. CBS | 82% | 70-90% |
| PPV | 83% | 70-91% |
| NPV | 84% | 74-91% |
| Marker | CBS | PSP | Utility |
|--------|-----|-----|---------|
| Total tau | Elevated | Elevated | Non-specific |
| p-tau181 | Variable | Elevated | PSP > CBS |
| p-tau217 | AD↑, CBD↔ | Moderate↑ | Differentiates CBS-AD |
| NfL | High | High | Disease burden |
| t-tau/Abeta42 | ↓ CBS | Normal | CBS-AD differentiation |
| Marker | CBS | PSP | Utility |
|--------|-----|-----|---------|
| p-tau217 | AD↑, CBD↔ | Moderate↑ | CBS-AD differentiation |
| p-tau181 | AD↑, CBD↔ | Elevated | PSP screening |
| NfL | High | High | Progression marker |
| GFAP | Variable | Variable | Comorbidities |
| Feature | Skin Biopsy Tau Seeding | CSF p-tau | Plasma p-tau |
|---------|-------------------------|-----------|--------------|
| Pathology specificity | High (seeding activity) | Moderate | Moderate |
| Invasiveness | Moderate | High (LP) | Low |
| Turnaround | 2-4 weeks | 1-2 days | 1-2 days |
| Cost | $$$ | $$ | $ |
| Standardization | Developing | Established | Established |
| 4R specificity | High | Low | Low |
The most robust diagnostic approach integrates multiple biomarkers:
This biomarker page connects to the broader CBS/PSP biomarker ecosystem:
Skin biopsy tau seeding represents a promising minimally invasive biomarker for antemortem diagnosis of CBS and PSP. By detecting the biologically active form of pathological tau through ultrasensitive seed amplification assays, this approach offers high specificity for 4R tauopathies and can help distinguish CBD from AD mimics in clinically ambiguous cases. While currently available primarily in research settings, skin biopsy tau seeding is poised to become an important tool in the diagnostic armamentarium for atypical parkinsonism.